scholarly journals Everolimus enhances TRAIL‐mediated anti‐tumor activity of liver resident natural killer cells in mice

2019 ◽  
Vol 33 (2) ◽  
pp. 229-243
Author(s):  
Jamilya Saparbay ◽  
Yuka Tanaka ◽  
Naoki Tanimine ◽  
Masahiro Ohira ◽  
Hideki Ohdan
Keyword(s):  
Natural Killer Cells ◽  
Natural Killer ◽  
Killer Cells ◽  
Anti Tumor Activity

scholarly journals The natural product chitosan enhances the anti-tumor activity of natural killer cells by activating dendritic cells

2018 ◽  
Vol 7 (6) ◽  
pp. e1431085 ◽  
Author(s):  
Xinxin Li ◽  
Wenjuan Dong ◽  
Ansel P. Nalin ◽  
Yufeng Wang ◽  
Pan Pan ◽  
...  
Keyword(s):  
Dendritic Cells ◽  
Natural Killer Cells ◽  
Natural Product ◽  
Natural Killer ◽  
Killer Cells ◽  
Anti Tumor Activity

Reinstating anti-tumor activity of Natural Killer cells

2019 ◽  
Vol 19 (10) ◽  
pp. e158
Author(s):  
Ceyda Caliskan ◽  
Michael Chrobok ◽  
Arnika Kathleen Wagner ◽  
Johanna Borg Bruchfeld ◽  
Hareth Nahi ◽  
...  
Keyword(s):  
Natural Killer Cells ◽  
Natural Killer ◽  
Killer Cells ◽  
Anti Tumor Activity

Involvement of neutrophils and natural killer cells in the anti-tumor activity of alemtuzumab in xenograft tumor models

2010 ◽  
Vol 51 (7) ◽  
pp. 1293-1304 ◽  
Author(s):  
William M. Siders ◽  
Jacqueline Shields ◽  
Carrie Garron ◽  
Yanping Hu ◽  
Paula Boutin ◽  
...  
Keyword(s):  
Natural Killer Cells ◽  
Natural Killer ◽  
Xenograft Tumor ◽  
Tumor Models ◽  
Killer Cells ◽  
Anti Tumor Activity

scholarly journals Antibody-mediated delivery of LIGHT to the tumor boosts Natural Killer cells and delays tumor progression

2020 ◽  
Author(s):  
Marco Stringhini ◽  
Jacqueline Mock ◽  
Vanessa Fontana ◽  
Patrizia Murer ◽  
Dario Neri
Keyword(s):  
Natural Killer Cells ◽  
Fusion Protein ◽  
Natural Killer ◽  
Tumor Therapy ◽  
Negative Control ◽  
Single Chain ◽  
Preclinical Development ◽  
Killer Cells ◽  
Immunocompetent Mice ◽  
Anti Tumor Activity

AbstractBackgroundLIGHT is a member of the TNF superfamily, which has been claimed to mediate anti-tumor activity on the basis of cancer cures observed in immunocompetent mice bearing transgenic LIGHT-expressing tumors. The preclinical development of a LIGHT-based therapeutic has been hindered by the lack of functional stability exhibited by this protein.MethodsHere, we describe the cloning, expression and characterization of five antibody-LIGHT fusion proteins, directed against the alternatively-spliced EDA domain of fibronectin, a conserved tumor-associated antigen.ResultsAmong the five tested formats, only the sequential fusion of the F8 antibody in single-chain diabody format, followed by the LIGHT homotrimer expressed as a single polypeptide, yielded a protein (termed “F8-LIGHT”) which was not prone to aggregation. A quantitative biodistribution analysis in tumor bearing mice, using radioiodinated protein preparations, confirmed that F8-LIGHT was able to preferentially accumulate at the tumor site, with a tumor-to-blood ratio of ca. five to one twenty-four hours after intravenous administration. Tumor therapy experiments, performed in two murine tumor models (CT26 and WEHI-164), featuring different levels of lymphocyte infiltration into the neoplastic mass, revealed that F8-LiGHT could significantly reduce tumor cell growth and was more potent than a similar fusion protein (KSF-LIGHT), directed against hen egg lysozyme and serving as negative control of irrelevant specificity in the mouse. At a mechanistic level, the activity of F8-LiGHT was mainly due to an intratumoral expansion of Natural Killer cells, whereas there was no evidence of expansion of CD8+ T cells, neither in the tumor, nor in draining lymph nodes.ConclusionWe developed a novel recombinant LIGHT fusion protein, able to accumulate at the site of disease and which displayed anti-tumor activity in two mouse models of cancer.

scholarly journals Enhancement of Anti-tumor Activity of Natural Killer Cells by BALL-1, a B Cell Lymphoma Line

1998 ◽  
Vol 89 (4) ◽  
pp. 427-435
Author(s):  
Mitsuomi Hirashima ◽  
Naoko Yoshida ◽  
Masako Seki ◽  
Hiroki Okada ◽  
Seishi Takamura ◽  
...  
Keyword(s):  
Natural Killer Cells ◽  
B Cell ◽  
Natural Killer ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Killer Cells ◽  
Lymphoma Line ◽  
Anti Tumor Activity

The bispecific immunoligand ULBP2-aCEA redirects natural killer cells to tumor cells and reveals potent anti-tumor activity against colon carcinoma

2013 ◽  
Vol 134 (12) ◽  
pp. 2829-2840 ◽  
Author(s):  
Achim Rothe ◽  
Ron D. Jachimowicz ◽  
Sven Borchmann ◽  
Marie Madlener ◽  
Jörg Keßler ◽  
...  
Keyword(s):  
Natural Killer Cells ◽  
Natural Killer ◽  
Tumor Cells ◽  
Colon Carcinoma ◽  
Killer Cells ◽  
Anti Tumor Activity
Sign in / Sign up

Export Citation Format

Share Document